Skip to main content

Advertisement

SpringerLink
Log in

Stay vigilant: a glitazone (pioglitazone) can hide a glitazar!

  • Letter to the Editors
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Duran-Sandoval D, Thomas AN, Bailleul B, Fruchart JC, Staels B (2003) Pharmacologie des agonistes PPARα et PPARγ et des activateurs mixtes en déveleppement clinique. Med Sci 19:819–825

    Google Scholar 

  2. Rubenstrunk A, Hanf R, Hum DW, Fruchart JC, Staels B (2007) Safety issues and prospects for future generations of PPAR modulators. Biochem Biophys Acta 1771:1065–1081

    Article  PubMed  CAS  Google Scholar 

  3. El-Hage J (2004) Preclinical and clinical safety assessments for PPAR agonists. http://www.fda.gov/cder/present/DIA2004/Elhage.ppt. Accessed 1 March 2005

  4. Food and Drug Administration (2010) FDA drug safety communication: ongoing safety review of actos (pioglitazone) and potential increased risk of bladder cancer after two years exposure. http://www.fda.gov/Drugs/DrugSafety/ucm226214.htm.. Accessed 1 October 2010

  5. Hillaire-Buys D, Faillie JL, Montastruc JL (2011) Pioglitazone and bladder cancer. Lancet 378:1543–1544

    Article  PubMed  Google Scholar 

  6. Neumann A, Weill A, Ricordeau P, Fagot JP, Alla F, Allemand H (2012) Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia. doi:10.1007/s00125-012-2538-9

  7. Sato K, Awasaki Y, Kandori H, Tanakamaru ZY, Nagai H, Baron D, Yamamoto M (2011) Suppressive effects of acid-forming diet against the tumorigenic potential of pioglitazone hydrochloride in the urinary bladder of male rats. Toxicol Appl Pharmacol 251:234–244

    Article  PubMed  CAS  Google Scholar 

  8. Long GG, Reynolds VL, Lopez-Martinez A, Ryan TE, White SL, Eldridge SR (2008) Urothelial carcinogenesis in the urinary bladder of rats treated with naveglitazar, a gamma-dominant PPAR alpha/gamma agonist: lack of evidence for urolithiasis as an inciting event. Toxicol Pathol 36:218–231

    Article  PubMed  CAS  Google Scholar 

  9. Long GG, Reynolds VL, Dochterman LW, Ryan TE (2009) Neoplastic and non-neoplastic changes in F-344 rats treated with Naveglitazar, a gamma-dominant PPAR alpha/gamma agonist. Toxicol Pathol 37:741–753

    Article  PubMed  CAS  Google Scholar 

  10. Egerod FL, Brünner N, Svendsen JE, Oleksiewicz MB (2010) PPARα and PPARγ are co-expressed, functional and show positive interactions in the rat urinary bladder urothelium. J Appl Toxicol 30:151–162

    PubMed  CAS  Google Scholar 

  11. Oleksiewicz MB, Southgate J, Iversen L, Egerod FL (2008) Rat urinary bladder carcinogenesis by dual-acting PPARα + γ agonists. PPAR Res 2008:103167

  12. Lubet RA, Fischer SM, Steele VE, Juliana MM, Desmond R, Grubbs CJ (2008) Rosiglitazone, a PPAR gamma agonist: potent promoter of hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers. Int J Cancer 123:2254–2259

    Article  PubMed  CAS  Google Scholar 

  13. Kasichayanula S, Liu X, Shyu WC, Zhang W, Pfister M, Griffen SC, Li T, LaCreta FP, Boulton DW (2011) Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects. Diabetes Obes Metab 13:47–54

    Google Scholar 

Download references

Disclosure statement

The authors declare that there is no conflict of interest associated with this manuscript.

Author information

Authors and Affiliations

  1. Department of Medical Pharmacology and Toxicology, CHRU Montpellier and INSERM U1058, Montpellier, France

    Dominique Hillaire-Buys

  2. Department of Medical Pharmacology and Toxicology, CHRU Montpellier, Montpellier, France

    Jean-Luc Faillie

  3. Department of Clinical Pharmacology and Pharmacoepidemiology, CHRU Toulouse and INSERM U1027, Toulouse, France

    Jean-Louis Montastruc

  4. Department of Medical Pharmacology and Toxicology, CHRU Montpellier and CNRS FRE3400, Montpellier, France

    Pierre Petit

Authors
  1. Dominique Hillaire-Buys
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jean-Luc Faillie
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jean-Louis Montastruc
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pierre Petit
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pierre Petit.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hillaire-Buys, D., Faillie, JL., Montastruc, JL. et al. Stay vigilant: a glitazone (pioglitazone) can hide a glitazar!. Eur J Clin Pharmacol 68, 1681–1683 (2012). https://doi.org/10.1007/s00228-012-1299-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-012-1299-1

Keywords

Search

Navigation